Andrew Hall has been named CBO at Nova Scotia immunotherapy biopharma IMV after spending more than 5 years as an executive director at Celgene. Hall also held several roles of increasing responsibility during his tenure at Merck, ending his time at the pharma giant as their global new products leader in the women’s health division